Literature DB >> 18172301

Twist promotes tumor cell growth through YB-1 expression.

Masaki Shiota1, Hiroto Izumi, Takamitsu Onitsuka, Naoya Miyamoto, Eiji Kashiwagi, Akihiko Kidani, Akira Yokomizo, Seiji Naito, Kimitoshi Kohno.   

Abstract

YB-1 controls gene expression through both transcriptional and translational mechanisms and is involved in various biological activities such as brain development, chemoresistance, and tumor progression. We have previously shown that YB-1 is overexpressed in cisplatin-resistant cells and is involved in resistance against DNA-damaging agents. Structural analysis of the YB-1 promoter reveals that several E-boxes may participate in the regulation of YB-1 expression. Here, we show that the E-box-binding transcription factor Twist is overexpressed in cisplatin-resistant cells and that YB-1 is a target gene of Twist. Silencing of either Twist or YB-1 expression induces G(1) phase cell cycle arrest of tumor cell growth. Significantly, reexpression of YB-1 led to increase colony formation when Twist expression was down-regulated by small interfering RNA. However, cotransfection of Twist expression plasmid could not increase colony formation when YB-1 expression was down-regulated. Collectively, these data suggest that YB-1 is a major downstream target of Twist. Both YB-1 and Twist expression could induce tumor progression, promoting cell growth and driving oncogenesis in various cancers. Thus, both YB-1 and Twist may represent promising molecular targets for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18172301     DOI: 10.1158/0008-5472.CAN-07-2981

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival.

Authors:  K S Bommert; M Effenberger; E Leich; M Küspert; D Murphy; C Langer; R Moll; S Janz; A Mottok; S Weissbach; A Rosenwald; R Bargou; K Bommert
Journal:  Leukemia       Date:  2012-07-09       Impact factor: 11.528

2.  SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities.

Authors:  Fen Yang; Luyang Sun; Qian Li; Xiao Han; Liandi Lei; Hua Zhang; Yongfeng Shang
Journal:  EMBO J       Date:  2011-10-07       Impact factor: 11.598

3.  YB-1, the E2F pathway, and regulation of tumor cell growth.

Authors:  Annette Lasham; Weini Samuel; Helen Cao; Rachna Patel; Reena Mehta; J Lewis Stern; Glen Reid; Adele G Woolley; Lance D Miller; Michael A Black; Andrew N Shelling; Cristin G Print; Antony W Braithwaite
Journal:  J Natl Cancer Inst       Date:  2011-12-28       Impact factor: 13.506

4.  Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.

Authors:  Jason Boyang Wu; Chen Shao; Xiangyan Li; Qinlong Li; Peizhen Hu; Changhong Shi; Yang Li; Yi-Ting Chen; Fei Yin; Chun-Peng Liao; Bangyan L Stiles; Haiyen E Zhau; Jean C Shih; Leland W K Chung
Journal:  J Clin Invest       Date:  2014-05-27       Impact factor: 14.808

5.  Interaction network analysis of YBX1 for identification of therapeutic targets in adenocarcinomas.

Authors:  Suriya Narayanan Murugesan; Birendra Singh Yadav; Pramod Kumar Maurya; Amit Chaudhary; Swati Singh; Ashutosh Mani
Journal:  J Biosci       Date:  2019-06       Impact factor: 1.826

6.  HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression.

Authors:  Jie Chen; Jun Xia; Yong-lin Yu; Si-qun Wang; Yi-bing Wei; Fei-yan Chen; Gang-yong Huang; Jing-sheng Shi
Journal:  Tumour Biol       Date:  2013-10-05

7.  Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.

Authors:  Masaki Shiota; Akira Yokomizo; Yasuhiro Tada; Junichi Inokuchi; Katsunori Tatsugami; Kentaro Kuroiwa; Takeshi Uchiumi; Naohiro Fujimoto; Narihito Seki; Seiji Naito
Journal:  Mol Endocrinol       Date:  2009-11-02

8.  Regulation of p21 by TWIST2 contributes to its tumor-suppressor function in human acute myeloid leukemia.

Authors:  X Zhang; W Ma; J Cui; H Yao; H Zhou; Y Ge; L Xiao; X Hu; B-H Liu; J Yang; Y-Y Li; S Chen; C J Eaves; D Wu; Y Zhao
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

9.  Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

Authors:  Golareh Habibi; Samuel Leung; Jennifer H Law; Karen Gelmon; Hamid Masoudi; Dmitry Turbin; Michael Pollak; Torsten O Nielsen; David Huntsman; Sandra E Dunn
Journal:  Breast Cancer Res       Date:  2008-10-16       Impact factor: 6.466

10.  Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.

Authors:  Edgar Dahl; Abdelaziz En-Nia; Frank Wiesmann; Renate Krings; Sonja Djudjaj; Elisabeth Breuer; Thomas Fuchs; Peter J Wild; Arndt Hartmann; Sandra E Dunn; Peter R Mertens
Journal:  BMC Cancer       Date:  2009-11-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.